戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ory neurons, but not both, using neurotropic adenoassociated and lentiviral vectors, cell-type-specif
2 tive strategy for tissue protection using an adenoassociated vector system containing erythropoietin
3 apy, we developed recombinant adenoviral and adenoassociated viral (AAV) FHIT vectors and tested thes
4                        To develop a modified adenoassociated viral (AAV) vector capable of efficient
5 down, or overexpression of ephrinA5 using an adenoassociated viral construct.
6                   We previously generated an adenoassociated viral gene therapy vector, rAAV-Delta264
7 a GFP reporter and packaged in a pseudotyped adenoassociated viral vector (AAV2/5).
8  the therapeutic efficacy of a re-engineered adenoassociated viral vector carrying I-1c (BNP116.I-1c)
9 received bilateral VMH microinjections of an adenoassociated viral vector containing either the SGLT1
10 blishing engineered immunity to HIV using an adenoassociated viral vector expressing a broadly neutra
11  mice carrying floxed Dicer1 alleles with an adenoassociated viral vector expressing Cre recombinase
12    Exogenous administration of VEGF-C via an adenoassociated viral vector improved hematopoietic reco
13 ts (four in the cerebellum) of a recombinant adenoassociated viral vector serotype 2/5 (rAAV2/5) enco
14                                     Thus the adenoassociated viral vector, rAAV-Delta264 CFTR, is a h
15 ocytes of adult Rosa26 reporter mice with an adenoassociated viral vector.
16 ering RNA (siRNA) delivered by a neurotropic adenoassociated viral vector.
17 an F.IX by hepatic gene transfer mediated by adenoassociated viral vector.
18 uid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamida
19 ne eye of 224 Wistar rats after injection of adenoassociated viral vectors (type 2) containing either
20                            Experiments using adenoassociated viral vectors expressing Ca(v)1.3 and ER
21 t by oral gene transfer, using adenoviral or adenoassociated viral vectors expressing the human FHIT
22 -expressed antigen, we exploited recombinant adenoassociated viral vectors that enabled us to vary po
23 s) with minimally increased hemostasis after adenoassociated viral-FVIII gene transfer and in treatme
24                                              Adenoassociated viral-mediated knockdown of miR29b in mi
25       To elucidate such actions, we used the adenoassociated virus (AAV) system to alter Npy gene exp
26 m of a minimal liver-specific promoter in an adenoassociated virus (AAV) that expresses a codon-optim
27 rt, we have adapted a commercially available adenoassociated virus (AAV) vector for siRNA delivery in
28  as to accommodate RPGR replacement genes in adenoassociated virus (AAV) vectors.
29             When expressed in cerebellum via adenoassociated virus (AAV) viral transfection in mice,
30 mine whether local retinal overexpression of adenoassociated virus (AAV)-ACE2 prevents or reverses di
31 diponectin gene (ADIPOQ) overexpression with adenoassociated virus (AAV)-ADIPOQ ameliorated cardiac i
32 we demonstrate that a single injection of an adenoassociated virus (AAV)-based COVID-19 vaccine elici
33 al trials have documented the feasibility of adenoassociated virus (AAV)-mediated gene therapy for he
34 t substantia nigra (SN), in combination with adenoassociated virus (AAV)-mediated overexpression of h
35                  In this study, we evaluated adenoassociated virus (AAV)-mediated programmed death-li
36 n the brain, we have examined the ability of adenoassociated virus (AAV)-mediated transduction of dop
37  post-SH, whether spontaneous or enhanced by adenoassociated virus (AAV)-mediated upregulation of Trk
38 SOD) or catalase (CAT) gene into recombinant adenoassociated virus (AAV).
39  cells was accomplished by transfection with adenoassociated virus (AAV-XIAP).
40 es were cloned and packaged in a recombinant adenoassociated virus (rAAV) containing a proximal 472-b
41 at3 activity was validated using recombinant adenoassociated virus (rAAV) vector-mediated PR Stat3 ex
42 s study assessed the efficacy of recombinant adenoassociated virus (rAAV)-encoding human heme oxygena
43          We investigated whether recombinant adenoassociated virus (rAAV)-mediated expression of dono
44            Three weeks after the recombinant adenoassociated virus (rAAV)-mediated orexin gene transf
45  expression in DRG neurons using recombinant adenoassociated virus (rAAV2/6) not only reduced Na(v)1.
46                   We showed that recombinant adenoassociated virus 1 was the most efficient vector fo
47 tor cells from C57BL/6 mice with recombinant adenoassociated virus 1-vector-expressing human alpha1 a
48 ondary structures at the 5'- and 3'- ends of adenoassociated virus 2 virion DNA was synthesized by li
49 at a single delivery of the sans cDNA by the adenoassociated virus 8 to the inner ear of newborn muta
50 avirus 2 (SARS-CoV-2) in a mouse model using adenoassociated virus and lentiviral vectors expressing
51 ches, such as gene therapy using dual-vector adenoassociated virus and transcriptional silencing of m
52  DNA into mitochondria efficiently, we fused adenoassociated virus capsid VP2 with a mitochondrial ta
53                                          The adenoassociated virus cassette accommodates genes of up
54  adult mice by the localized injection of an adenoassociated virus expressing Cre recombinase into fl
55                                 Injection of adenoassociated virus expressing this ribozyme led to ax
56           Forced Notch pathway activation by adenoassociated virus gene transfer of activated Notch1
57                               Using a tracer adenoassociated virus in the PMv of adult DAT(Cre); Kiss
58 olution microscopy, adenovirus transduction, adenoassociated virus injection, structural modeling, su
59 olution microscopy, adenovirus transduction, adenoassociated virus injection, structural modeling, su
60 ampi of APP+presenilin-1 bigenic mice via an adenoassociated virus serotype 2/1 hybrid (AAV2/1-FGF2).
61 ombination approach using self-complementary adenoassociated virus serotype 9 (scAAV9) vectors in hem
62  (IDOL) overexpression, using liver-targeted adenoassociated virus serotype DJ/8 (AAV-DJ/8) in BTBR w
63                                      We used adenoassociated virus to deliver the human gene for SOD2
64 ed liver progenitor cells with a recombinant adenoassociated virus vector and implies a novel approac
65 ral subthalamic nucleus (STN) infusion of an adenoassociated virus vector expressing glutamic acid de
66 ls to avoid both problems, using recombinant adenoassociated virus vector expressing human alpha1-ant
67 e after transduction of muscle or liver with adenoassociated virus vector, as well as new nonviral ge
68                                     The same adenoassociated virus vectors, however, were largely ine
69 mong five different serotypes of recombinant adenoassociated virus vectors.
70          Administration of decoy-expressing (adenoassociated virus) AAV2.retro and AAV6.2 vectors by
71 minant-negative constructs delivered by AAV (adenoassociated virus) vector transfer.
72                      Using rAAV (recombinant adenoassociated virus) viral vectors, high levels of Del
73 ed in the core of cocaine-naive rats with an adenoassociated virus, long-term depression was inhibite
74 tracing of mature mouse hepatocytes using an adenoassociated virus-driven Cre recombinase.
75 ssion of InsP(3)R-mediated Ca2+ signaling by adenoassociated virus-mediated expression of the inosito
76                            Here we show that adenoassociated virus-mediated overexpression of human A